Key result
R-CHOP achieves disease remission at 6 months in rare primary endobronchial DLBCL.
Why the study?
Primary pulmonary lymphomas are rare, and primary endobronchial involvement of high-grade non-Hodgkin's lymphoma is even more exceptional with limited clinical descriptions.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Primary endobronchial non-Hodgkin's lymphoma is extremely rare but should be included in the differential diagnosis of uncharacteristic endobronchial lesions.
To the Editor: Primary pulmonary lymphomas (PPLs) are uncommon and represent only 0.5% to 1% of all pulmonary neoplasms. They are defined as a clonal lymphoid proliferation in 1 or both lungs, parenchymal and/or endobrobronchial, with no extra-thoracic involvement at the time of diagnosis or during the following 3-month period. Regarding the thoracic disease, endobronchial involvement is even less common than parenchymal disease, appearing mainly as a part of systemic disease or contiguous with Hodgkin’s lymphoma.1,2 Here we report a rare case of a high-grade primary pulmonary, endobronchial non-Hodgkin’s Lymphoma (NHL). A 72-year-old, life-long nonsmoker woman, presented with gradually worsening intermittent hemoptysis of 4 years’ duration. Her history was significant for hypertension, dyslipidemia, atrial fibrillation, and Graves’ disease, the latter treated with radioactive iodine. A computed tomography (CT) of the chest revealed segmental atelectasis involving lingula and a left hilar soft tissue mass (Fig. 1, white arrow). A flexible bronchoscopy revealed irregular submucosal infiltration involving the distal third of the left main bronchus. (Fig. 2) The histologic examination of the endobronchial biopsy was consistent with a high-grade diffuse NHL of large B-cell lymphoma (DLBCL) variety. The positron emission tomography (PET-CT) study showed uptake only in the region of the left hilum. A bone marrow biopsy was unrevealing. The patient received 4 cycles of chemotheraphy with R-CHOP (Rituximab, Cyclophoshhamide, Doxorubicin, Vincristine, and Prednisona). At the time of this report, 6 months since the diagnosis, the disease remained under remission by CT and bronchoscopy.FIGURE 1: Atectasis in the lingual.FIGURE 2: Tumor in the distal third of the left main bronchus.Primary pulmonary NHLs are rare, representing around 0.4% of all malignant lymphomas. Primary endobronchial involvement of the NHL is even more exceptional. Mucosa-associated lymphoid tissue (MALT) NHL is the most common histologic subtype involving the endobronchial tree. The patients are generally asymtomatic, with slow progression and late dissemination of the disease. The treatment may vary from a strict monitoring to surgery, radiotherapy, or chemotherapy. In contrast, aggressive NHLs are much less common and may appear as a result of a transformation of an asymtomatic lymphoma, post-transplant lymphoproliferative disorder, or human immunodeficiency virus infection.1,2 In these patients, the prognosis is clearly worse than in patients with MALT and require an aggressive treatment. Solomonov and colleagues, in 2008, reviewed 441 patients with NHL diagnosis over a period of 7 years. In this report, 8 patients (1.8%) had localized lung disease, 5 of them in the form of mediastinal masses and in 3 cases exclusively with isolated endobronchial involvement. The main symptom was dyspnea. Even though the literature describes that the main histological type of PPL is MALT, only one of the patients in this series exhibited the condition, whereas in the remaining patients, the histologic findings were that of DLBCL.3 According to published data, DLBCL with a primary pulmonary location represents 11% to 19% of all PPL, although its incidence is probably higher. The underdiagnosis could be due to the slower growth and the infrequent involvement of the mediastinum and extratoracic locations, the latter of course associated with a worse prognosis. In summary, the lung is a common site for a secondary involvement of malignant lymphomas, with an incidence of 25% to 40%; primary NHLs involving the endobronchial tree are extremely rare.4,5 Yet, they should be included in the differential diagnosis of uncharacteristic endobronchial lesions.
No takes yet. Share an insight, caveat, or question.
Jodra et al. (2016) conducted a case report in Primary pulmonary endobronchial non-Hodgkin's Lymphoma (n=1). R-CHOP chemotherapy was evaluated on Disease remission. R-CHOP chemotherapy resulted in disease remission at 6 months in a 72-year-old woman with a rare primary pulmonary endobronchial high-grade diffuse large B-cell lymphoma.
Synapse has enriched 10 related papers. Consider them for comparative context: